

Release of escrowed securities

Lapse of unlisted share options

Melbourne, Australia, 19 November 2018: Cancer therapy developer Invion Limited (ASX:IVX) notifies the market regarding the release of securities from escrow.

On 4 December 2017, subsequent to shareholder approval at the 2017 AGM, 2,750,000,000 shares were issued in consideration for the Australia and New Zealand rights to commercialise and distribute Photosoft™ as a treatment for cancers.

These shares were escrowed for a period of 12 months, and will be released from escrow on 4 December 2018.

The release of the escrowed shares means that Invion will no longer have a relevant interest in its own issued shares. Accordingly, a notice of ceasing to be a substantial holder for Invion is attached to this announcement.

On 9 November 2018, 19,700,000 share options lapsed, unexercised.

An Appendix 3B accompanies this announcement.

About Invion

Invion is a clinical-stage life-sciences company that is leading the global clinical development of the Photosoft™ technology for the treatment of cancers. Invion has been appointed exclusive distributor and licensee in Australia and New Zealand of Photosoft™. The appointment has been made by technology licensor, The Cho Group, a Hong Kong based group that has funded and successfully commercialised a number of unique and advanced technologies. Via an R&D services agreement between the two entities, the research and clinical trials of Photosoft™ are funded by The Cho Group. Invion has an alliance with leading Australian medical research institute, Hudson Institute of Medical Research, for the Photosoft™ research program.

About Photodynamic Therapy (PDT)

Invion is developing Photosoft™ technology as an improved next-generation Photodynamic Therapy. PDT is a clinically approved, minimally invasive therapeutic treatment that uses non-toxic photosensitisers and visible light in combination with oxygen to produce cytotoxic-reactive oxygen that kills malignant cells, shuts down tumours and stimulates the immune system. In contrast to surgery, or radiotherapy and chemotherapy which are mostly immunosuppressive, PDT causes acute inflammation, expression of heat-shock proteins, and invasion and infiltration of a tumour by leukocytes.

Investor enquiries: Managing Director & CEO, Dr Greg Collier
T: +61 3 9081 6005 E: investor@inviongroup.com